IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by Beacon Financial Group

Beacon Financial Group decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 4.9% in the fourth quarter, HoldingsChannel reports. The firm owned 3,604 shares of the medical research company’s stock after selling 187 shares during the quarter. Beacon Financial Group’s holdings in IQVIA were worth $708,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Capital Performance Advisors LLP acquired a new stake in shares of IQVIA during the third quarter worth about $27,000. Synergy Asset Management LLC acquired a new stake in shares of IQVIA during the fourth quarter worth about $33,000. Avior Wealth Management LLC lifted its holdings in shares of IQVIA by 117.6% during the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock worth $38,000 after purchasing an additional 87 shares during the period. Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares during the period. Finally, Concord Wealth Partners acquired a new position in IQVIA in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Insiders Place Their Bets

In related news, Director John G. Danhakl bought 1,275 shares of the business’s stock in a transaction on Tuesday, December 3rd. The stock was acquired at an average cost of $200.58 per share, with a total value of $255,739.50. Following the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on IQV. The Goldman Sachs Group decreased their price target on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a report on Friday, November 1st. UBS Group decreased their price target on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. Stephens began coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price target for the company. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Barclays reduced their target price on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $251.67.

IQVIA Stock Down 1.6 %

NYSE IQV opened at $197.64 on Thursday. The business has a fifty day moving average price of $200.77 and a 200 day moving average price of $218.81. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The company has a market cap of $35.87 billion, a P/E ratio of 26.35, a P/E/G ratio of 2.25 and a beta of 1.48.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. Research analysts anticipate that IQVIA Holdings Inc. will post 10.81 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.